Tyrosine kinase inhibitors (TKIs) are associated with cardiac toxicity, which may be caused
by mitochondrial toxicity. The underlying mechanisms are currently unclear and require …

Cardiovascular disease has recently been suggested to be a significant complication of
cancer treatment with several kinase inhibitors. In some cases, the mechanisms leading to …

Tyrosine kinase inhibitors (TKIs) are anticancer drugs with a lesser toxicity than classical
chemotherapeutic agents but still with a narrow therapeutic window. While hepatotoxicity is …

Sunitinib is cardiotoxic, but the mechanisms are not entirely clear. We aimed to enlarge our
knowledge about the role of mitochondria in cardiac toxicity of sunitinib in vitro and in vivo …

Tyrosine kinase inhibitors (TKIs) can cause skeletal muscle toxicity in patients, but the
underlying mechanisms are mostly unclear. The goal of the current study was to better …

Tyrosine kinase inhibitors (TKIs) are targeted therapies rapidly becoming favored over
conventional cytotoxic chemotherapeutics. Our study investigates two FDA approved TKIs, D …

Background: Tyrosine kinase inhibitors (TKIs) have dramatically improved cancer treatment
but are known to cause cardiotoxicity. The pathophysiological consequences of TKI therapy …

Mitochondria are organelles that play a pivotal role in the production of energy in cells, and
vital to the maintenance of cellular homeostasis due to the regulation of many biochemical …

Imatinib is a tyrosine kinase inhibitor widely administered against chronic myeloid leukemia.
On the other hand, drug-induced kidney proximal tubular injury, electrolytes disturbances …

Tyrosine kinase inhibitors (TKIs) have advanced cancer treatment and prognosis but have
also resulted in adverse effects such as fatigue, diarrhea, hypothyroidism, and other …